Effect of simvastatin, probiotic and NAC drugs as adjuvant therapy to standard treatment in the eradication of Helicobacter pylori

Determining the efficacy of quadruple standard regimen combined with simvastatin, probiotic, and NAC as adjuvant therapy for H. Pylori eradication and comparing to standard treatment

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220406054431N1

Enrollment

168

Registered

2022-05-08

Start date

2022-05-10

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

Interventions

Intervention 1: The standard four-drug protocol recipient group (metronidazole kimidaro 250 mg, amoxicillin-producing 1000 mg, pentaprazole kimidaro 40 mg and bismuth kimidaro 120 mg) all twice daily

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: People over the age of 18 and under 65 With positive stool antigen test or endoscopy for Helicobacter pylori

Exclusion criteria

Exclusion criteria: History of heart, kidney and liver failure Diabetes Developing an active cancer Drug and alcohol addiction Recent history of gastrointestinal bleeding Get previous treatment

Design outcomes

Primary

Measure	Time frame
Helicobacter pylori eradication rate. Timepoint: Beginning of the study and one month later. Method of measurement: Stool test for Helicobacter pylori antigen.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElena Lak

Shahid Beheshti University of Medical Sciences

dr_elenalak@yahoo.com+98 21 7343 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026